Europe Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022 - 2028

The Europe Vulvovaginal Candidiasis Treatment Market would witness market growth of 4.2% CAGR during the forecast period (2022-2028).

The need for vulvovaginal candidiasis treatment is growing as a result of the rising prevalence of the disease, which further indicates the rising demand for better treatment options. Also, the growing number of hospital-acquired infections, the continued development of new antifungal drugs, growing healthcare spending, and the advancement in healthcare infrastructure are some of the factors supporting market growth for the vulvovaginal candidiasis treatment market.

The continued increase in the use of antibiotics is resulting high prevalence of vaginal yeast infection among women. Also, the cases of cardiovascular diseases, neurological diseases, cancer as well as gastrointestinal disease have resulted in growing consumption of broad-spectrum antibiotics across the globe which may result in rising cases of vulvovaginal candidiasis. This raises the need for treatment of vulvovaginal candidiasis leading to market growth.

Various advances in the understanding of vulvovaginal candidiasis as an immunopathology, as well as the mechanistic role of the inflammasome, candidalysin, and PRR-mediated signaling at vaginal mucosa, have opened up new paths for scientific exploration. The consideration of vulvovaginal candidiasis as an immunopathology is an inevitable shift. As the incidence of VVC across the globe is expected to rise in the upcoming years, improved treatment modalities and diagnosing facilities will be required in the near future.

In 2019, about 105,200 people had HIV infection in the United Kingdom; out of these, 6600 cases were predicted undiagnosed. Also, obesity continued to be among the region's significant concerns of public health. Being overweight and obese raises the risk of developing various diseases. Obese people are more at risk of insulin resistance and high blood sugar level, and the development of diabetes. The increased blood sugar level could result in overgrowth of Candida, especially in the genitals or bladder. Furthermore, the consumption of antibiotics for the treatment of the urinary tract could also lead to candida-related infection. As a result, the rising prevalence of obesity would further raise the occurrence of vulvovaginal candidiasis in the region.

The Germany market dominated the Europe Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $88.5 million by 2028. The UK market is exhibiting a CAGR of 3.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Global Vulvovaginal Candidiasis Treatment Market will Hit $1.3 Billion by 2028, at a CAGR of 4.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Route of Administration

• Oral
• Intravenous
• Topical

By Drug Class

• Fluconazole
• Clotrimazole
• Terconazole
• Terbinafine
• Nystatin
• Ketoconazole
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Bayer AG
• Bristol Myers Squibb Company
• Pfizer, Inc.
• Astellas Pharma, Inc.
• Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
• Basilea Pharmaceutica Ltd.
• Scynexis, Inc.
• Grupo Ferrer Internacional S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
1.4.2 Europe Vulvovaginal Candidiasis Treatment Market, by Route of Administration
1.4.3 Europe Vulvovaginal Candidiasis Treatment Market, by Drug Class
1.4.4 Europe Vulvovaginal Candidiasis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
3.1 Europe Retail Pharmacy Market by Country
3.2 Europe Hospital Pharmacy Market by Country
3.3 Europe Online Pharmacy Market by Country

Chapter 4. Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
4.1 Europe Oral Market by Country
4.2 Europe Intravenous Market by Country
4.3 Europe Topical Market by Country

Chapter 5. Europe Vulvovaginal Candidiasis Treatment Market by Drug Class
5.1 Europe Fluconazole Market by Country
5.2 Europe Clotrimazole Market by Country
5.3 Europe Terconazole Market by Country
5.4 Europe Terbinafine Market by Country
5.5 Europe Nystatin Market by Country
5.6 Europe Ketoconazole Market by Country
5.7 Europe Others Market by Country

Chapter 6. Europe Vulvovaginal Candidiasis Treatment Market by Country
6.1 Germany Vulvovaginal Candidiasis Treatment Market
6.1.1 Germany Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.2 Germany Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.3 Germany Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 UK Vulvovaginal Candidiasis Treatment Market
6.2.1 UK Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.2 UK Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.3 UK Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 France Vulvovaginal Candidiasis Treatment Market
6.3.1 France Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.2 France Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.3 France Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 Russia Vulvovaginal Candidiasis Treatment Market
6.4.1 Russia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.2 Russia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.3 Russia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.5 Spain Vulvovaginal Candidiasis Treatment Market
6.5.1 Spain Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.5.2 Spain Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.5.3 Spain Vulvovaginal Candidiasis Treatment Market by Drug Class
6.6 Italy Vulvovaginal Candidiasis Treatment Market
6.6.1 Italy Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.6.2 Italy Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.6.3 Italy Vulvovaginal Candidiasis Treatment Market by Drug Class
6.7 Rest of Europe Vulvovaginal Candidiasis Treatment Market
6.7.1 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.7.2 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.7.3 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Drug Class

Chapter 7. Company Profiles
7.1 Bayer AG
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional & Segmental Analysis
7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Trials and Approvals:
7.6 Basilea Pharmaceutica Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Trials and Approvals:
7.8 Grupo Ferrer Internacional S.A.
7.8.1 Company Overview

TABLE 1 Europe Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 2 Europe Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 3 Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 4 Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 5 Europe Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 12 Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 13 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Intravenous Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Intravenous Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Topical Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Topical Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 20 Europe Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 21 Europe Fluconazole Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Fluconazole Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Clotrimazole Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Clotrimazole Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Terconazole Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe Terconazole Market by Country, 2022 - 2028, USD Million
TABLE 27 Europe Terbinafine Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Terbinafine Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Nystatin Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Nystatin Market by Country, 2022 - 2028, USD Million
TABLE 31 Europe Ketoconazole Market by Country, 2018 - 2021, USD Million
TABLE 32 Europe Ketoconazole Market by Country, 2022 - 2028, USD Million
TABLE 33 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 34 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 35 Europe Vulvovaginal Candidiasis Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 Europe Vulvovaginal Candidiasis Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 Germany Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 38 Germany Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 39 Germany Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 40 Germany Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 41 Germany Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 Germany Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 Germany Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 44 Germany Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 45 UK Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 46 UK Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 47 UK Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 48 UK Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 49 UK Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 50 UK Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 51 UK Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 52 UK Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 53 France Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 54 France Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 55 France Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 56 France Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 57 France Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 58 France Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 59 France Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 60 France Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 61 Russia Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 62 Russia Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 63 Russia Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 64 Russia Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 65 Russia Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Russia Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Russia Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 68 Russia Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 69 Spain Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 70 Spain Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 71 Spain Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 72 Spain Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 73 Spain Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 74 Spain Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 75 Spain Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 76 Spain Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 77 Italy Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 78 Italy Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 79 Italy Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 80 Italy Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 81 Italy Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Italy Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Italy Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 84 Italy Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 87 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 88 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 89 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 90 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 91 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 92 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 93 Key Information – Bayer AG
TABLE 94 Key Information – Pfizer, Inc.
TABLE 95 Key Information – Bristol Myers Squibb Company
TABLE 96 key information – Astellas Pharma, Inc.
TABLE 97 Key Information – Mycovia Pharmaceuticals, Inc.
TABLE 98 Key Information – Basilea Pharmaceutica Ltd.
TABLE 99 Key Information – Scynexis, Inc.
TABLE 100 Key Information – Grupo Ferrer Internacional S.A.

List of Figures
FIG 1 Methodology for the research